Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allarity Therapeutics (ALLR) Retained Earnings (2024 - 2025)

Allarity Therapeutics' Retained Earnings history spans 2 years, with the latest figure at -$1.0 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 99.14% year-over-year to -$1.0 million; the TTM value through Dec 2025 reached -$1.0 million, up 99.14%, while the annual FY2025 figure was -$1.0 million, 99.14% up from the prior year.
  • Retained Earnings reached -$1.0 million in Q4 2025 per ALLR's latest filing, up from -$2.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$386000.0 in Q1 2024 to a low of -$121.7 million in Q1 2025.